医护专业人士

A close up shot of a green stethoscope on top of a doctor's notes

肝病可能是沉默的,但它正在上升。

每四个加拿大人,就有一个可能受到肝脏疾病的影响,包括男性,女性和儿童 。 作为医疗保健专业人员,您需要获得可靠的信息和资源,以帮助您和您的患者。 加拿大肝脏基金会与加拿大肝脏研究协会(CASL),学术和研究机构,医院,政府机构等人员协会合作,协助提供循证信息和实用工具和资源,帮助您通过预防,诊断,治疗和护理来改善社区的肝脏健康。

注意: 本页面上的信息链接,是根据其内容、来源以及对于网站访问者潜在用途而选择的,并且作为一项公共服务,提供与肝脏健康相关的信息。 但是,加拿大肝脏基金会对这些网站上的任何信息不承担任何责任,在此页面上添加链接,也不代表加拿大肝脏基金会对任何相关组织或个人的认证。

liver risk factors
风险因素  
liver diagnostics
诊断  
clinical practice guidelines
临床实践指南  
liver resources
资源  
liver meetings and conferences
会议与研讨  

风险因素

肝病通常难以诊断,因为其症状可能含糊不清,容易与其他健康问题混淆。 在某些情况下,一个人根本没有症状,但肝脏可能已经受到重大损害。 危险因素可能会因100 +种不同肝病形式而非常不同,因此肝脏疾病的患者也不可能有统一“特征” – 它可以影响任何年龄阶段的、任何社会经济地位和任何种族的背景的任何人。 医疗保健专业人员必须了解肝脏疾病的一些更常见的危险因素和症状,以便可以主动寻找这些警告标志,并采取必要步骤(例如,了解更多信息,进行适当的检查,咨询专科医生),因为肝脏疾病的早期诊断,会为您和患者提供有效应对肝脏疾病的最佳机会。

一些失代偿期肝病更常见和可识别的 风险因素 可能包括:

  • 肥胖/糖尿病(即代谢综合征)
  • 接触某些化学物质或毒素,包括处方药和非处方药,草药和娱乐“街头药物”(即:对乙酰氨基酚过量,与酒精混合使用药物)
  • 重度酒精摄取
  • 肝病家族史
  • 接触血液或体液中的乙型或丙型肝炎病毒:
    • 1990年之前,在加拿大进行过输血、血液制品或器官捐赠或移植
    • 注射吸毒或鼻腔吸毒,或共用吸毒用具
    • 出生于乙型肝炎和丙型肝炎较为普遍的地区(如中亚,东亚和南亚; 奥斯特拉西亚和大洋洲;东欧,撒哈拉以南非洲以及北非/中东地区)
    • 未妥善消毒的设备(牙科手术,肾/血液透析治疗,纹身和身体穿孔等)
    • 无保护的性交

一些失代偿期肝病更常见和可识别的 症状 包括:

  • 黄疸(血液中胆红素升高引起的皮肤和眼睛发黄)
  • 恶心,呕吐或食欲不振
  • 肝脏腹部肿胀(腹水)或压痛
  • 慢性疲劳
  • 皮肤痒(瘙痒)
  • 深色尿液
  • 苍白色或血色大便
  • 痴呆状迷乱(肝性脑病)

本页面上的信息链接,是根据其内容、来源及其对于网站访问者的潜在用途而选择的,且作为一项公共服务,提供与肝脏健康相关的信息。 但是,加拿大肝脏基金会对这些网站上的任何信息不承担任何责任;在此页面上添加链接,也不代表加拿大肝脏基金会对任何相关组织或个人的认证。

诊断

肝病的诊断和治疗,始于在患者咨询期间收集信息,包括患者/家族史,身体检查和肝脏检查。 这些信息的组合,帮助你决定如何有效地识别,应对和解决患者肝脏健康问题。 显示健康肝脏与脂肪肝相比肝硬化肝脏组成的图表。加拿大肝脏基金会鼓励所有主要医疗保健提供者与患者坦诚讨论肝脏疾病可能的危险因素,包括吸毒(过去或现在),饮酒,性活动,饮食和运动以及药物管理(处方,非处方和补充/替代)等方面。 CLF还建议所有主要医疗保健提供者,将肝功能测试作为常规身体检查时血液检查的一部分。 这些初步的肝功能测试,将有助于明确是否需要进一步的检查:

丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)

ALT和AST测试测量血液中这些酶的量。 ALT和AST主要在肝细胞中发现,但如果肝细胞受损,这些酶可能从肝细胞中泄漏出来,进入血液。 大多数ALT和AST水平的升高可能是肝脏损伤的指标,但不能反映肝脏的实际功能。

碱性磷酸酶(ALP)

ALP测试测量血液中该酶的量。 ALP主要在肝脏中产生,并且最常用于检测胆道系统中的阻塞。 这种酶的升高可以在许多肝脏疾病中发现,包括胆结石疾病,酒精滥用,药物诱发的肝炎和原发性胆汁性胆管炎。升高的ALP水平可能是肝脏或胆管损伤的标示。 

总胆红素,国际标准化比例(INR)和血清白蛋白

这些是肝功能的替代标志物,当有明显的代偿失调时,这些实验室检查结果将是异常的。 异常程度反映了肝脏的余留功能。 所有三个实验室指标是Child-Pugh评分的组成部分,该评分为全球使用的肝功能失代偿的评分系统。 INR和胆红素以及血清肌酐(严重肝功能障碍时肾功能异常的标志物),也是MELD评分(终末期肝病模型)的组成部分。 MELD评分是美国唯一获准使用的评分,用以确定肝移植等候名单分配和分诊。 所有加拿大肝移植中心也使用MELD评分及Child-Pugh Score评分。

其他诊断工具和计算器

iMD健康加拿大 目的:屡获殊荣的互动式触摸屏电脑终端,帮助医生在护理点向患者及其护理人员更有效地传达肝脏疾病信息。 该系统为医生及其患者提供信息,包括:图像,理解,生活方式,处方和非处方药物,消费者保健和专业工具。 在这里查找更多信息。 (请注意:这是一个外部网站,可用信息是英文)
LiverTox 目的:最新,准确,易于获取有关因处方药和非处方药,草药和膳食补充剂引起的肝损伤的诊断,原因,频率,模式和管理信息。 信息和搜索数据库 (请注意:这是一个外部网站,可用信息是英文)
终末期肝病评分模型(MELD评分) 目的:评估肝脏疾病的严重程度,并确定预后及接受肝移植的优先级。 信息和计算器 (请注意:这是一个外部网站,可用信息是英文)
儿科终末期肝病评分(PELD评分) 目的:评估12年龄儿童肝脏疾病的严重程度,并确定预后及接受肝移植的优先次序。 信息和计算器 (请注意:这是一个外部网站,可用信息是英文)

目的:评估肝硬化的严重程度。 信息和计算器 (请注意:这是一个外部网站,可用信息是英文)

Maddrey对酒精性肝炎的判别功能 目的:预测酒精相关性肝炎的预后,并识别患者,以使用类固醇进行治疗。 信息和计算器 (请注意:这是一个外部网站,可用信息是英文)

临床肝性脑病分期量表(CHESS) Christopher Rose博士(CRCHUM,蒙特利尔大学)和Philip Wong博士(麦吉尔大学健康中心)2016年XNUMX月 介绍信 点击此处。 (可用 点击此处。 用法语)。 可用比例表 点击此处。 (可用 点击此处。 用法语) 肝性脑病症状跟踪和监测工具(用于患者和护理人员) Christopher Rose博士(CRCHUM,蒙特利尔大学)和Philip Wong博士(麦吉尔大学健康中心)2016年XNUMX月 在这里下载症状跟踪器点击此处为法文信息)。

Reach-B 评分 目的:预测慢性乙型肝炎患者的肝癌风险。 在这里查找更多信息。 (请注意:这是一个外部网站,可用信息是英文)

本页面上的信息链接,是根据其内容、来源及其对于网站访问者的潜在用途而选择的,且作为一项公共服务,提供与肝脏健康相关的信息。 但是,加拿大肝脏基金会对这些网站上的任何信息不承担任何责任;在此页面上添加链接,也不代表加拿大肝脏基金会对任何相关组织或个人的认证。

临床实践指南

专家已经开发了以下基于证据的临床实践指南,其中包括对护理诊断,治疗和预防方面的首选方法的建议。 以下提供的链接信息的相关性与科学价值,已经过加拿大肝脏基金会医疗咨询委员会的审查,并得到了来源许可。

一个帮助临床医生和患者参与对话的计划,讨论关于不必要的测试和治疗,以及明智和有效的护理选择。

医生和病人应该提出的五点问题
2017年XNUMX月
July 2017 (法语版点击此处)

非酒精性脂肪性肝病的诊断和治疗:
美国肝病研究协会的实践指南

美国肝病研究协会实践指南,美国胃肠病学会和美国胃肠病学会
Journal of Hepatology,Vol。 67,第1号,1月2018

NASPGHAN儿童非酒精性脂肪肝病诊断与治疗临床实践指南
NAFLD专家委员会(ECON)和北美儿科胃肠病学,肝病与营养学会(NASPGHAN)的建议,
Journal of Pediatric Gastroenterology and Nutrition,February 2017

(请注意:这些是外部资源,可用信息是英文)

棘球菌多细胞病:卫生保健提供者的信息
公共卫生安大略省,6月2017

棘球菌多细胞病:临床医生知道的五件事
公共卫生安大略省,6月2017

(请注意:这些是外部资源,可用信息是英文)

Diagnosis and Management of Hemochromatosis 2011 Practice Guideline by the American Association for the Study of Liver Diseases Journal of Hepatology, Vol. 54, No. 1, 2011 How I Treat Hemochromatosis Journal Blood, Vol. 116, No. 3, July 2010 (public access) (Please note: these are external resources, information available is in English)

Hepatic Encephalopathy in Chronic Liver Disease 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Journal of Hepatology, Vol. 60, Issue 2, Pages 715-735, August 2014 Clinical Hepatic Encephalopathy Staging Scale (CHESS) By Dr. Christopher Rose (CRCHUM, University of Montreal) and Dr. Philip Wong (McGill University Health Centre), June 2016 Introductory letter available here. (Available in French here and here) Hepatic Encephalopathy Symptom Tracker and Monitoring Tool (for Patients & Caregivers) By Dr. Christopher Rose (CRCHUM, University of Montreal) and Dr. Philip Wong (McGill University Health Centre), June 2016 (Available in French here)

Caring for the Child with Chronic Hepatitis B Infection By Constance O’Connor, MN and Simon Ling, MBChB The Hospital for Sick Children, Toronto, Ontario, Canada, June 2014 Primary Care Management of Hepatitis B – Quick Reference Public Health Agency of Canada, March 2013 Pour la version française, cliquez ici. Management of Chronic Hepatitis B: Consensus guidelines from the Canadian Association for the Study of the Liver  Canadian Journal of Gastroenterology and Hepatology, December 2012 Management of Chronic Hepatitis B: Canadian Association for the Study of the Liver Consensus Guidelines  Canadian Journal of Gastroenterology and Hepatology, June 2007 (Please note: these are external resources, information available is in English)

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver Consensus Guidelines from the Canadian Association for the Study of the Liver CMAJ, June 4, 2018, Volume 190, Issue 22 Hepatitis C Screening & Testing Quick Reference Guide Canadian Liver Foundation  (June 2016) Pour la version en français, cliquez ici pour télécharger. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment.  Mark Hull, Stephen Shafran, Alex Wong, et al. Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 2016, Article ID 4385643, 34 pages, 2016 CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults Canadian Journal of Infectious Diseases & Medical Microbiology, October 2014 (Please note: these are external resources, information available is in English)

Hepatocellular Carcinoma: Consensus, controversies and future directions: A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting Canadian Journal of Gastroenterology and Hepatology, Vol. 29, No. 4, May 2015 Focal Tumour Ablation in Ontario: Recommendations Report 2015 Focal Tumour Ablation Advisory Committee, Cancer Care Ontario / Action Cancer Ontario Multidisciplinary Canadian Consensus Recommendations for the Management and Treatment of Hepatocellular Carcinoma Journal of Current Oncology, Vol. 18, No. 5, 2011 (Please note: these are external resources, information available is in English)

Hepatology 2017: A Clinical Textbook By Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer. To download free PDF or to buy a copy of the book, click here. (Please note: these are external resources, information available is in English)

Guidance on the Use of Increased Infectious Risk Donors for Organ Transplantation: The CST/CNTRP Increased Risk Donor Working Group Journal Transplantation, September 2014 Evaluation of the Pediatric Patient for Liver Transplantation: 2014 Practice Guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Journal of Hepatology, Vol. 60, Issue 1, Pages 362-398, July 2014 (Please note: these are external resources, information available is in English)

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis 2017 Clinical Practice Guidelines by the European Association for the Study of the Liver (EASL) Journal of Hepatology, Vol, 67, No. 145-172, 2017 Patient Guide for Primary Biliary Cholangitis (PBC): Living with your diagnosis  2017 Patient Guide by The PBC Network, endorsed and reviewed by the European Association for the Study of the Liver (EASL) AASLD Practice Guidelines: Primary Biliary Cirrhosis 2009 Practice Guideline by the American Association for the Study of Liver Diseases Journal of Hepatology, Vol. 50, No. 1, 2009 (Please note: these are external resources, information available is in English)

The information links on this page have been chosen based on their content, source and potential usefulness for our site visitors and are provided here as a public service with regard to liver-related issues. However, the Canadian Liver Foundation assumes no responsibility for any information on these sites and the inclusion of a link on this page does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.

您和患者的资源

以下工具和资源可用于进一步帮助您获取有关预防,诊断,治疗和护理各种形式肝病的信息。 如果您想了解各种形式的肝脏疾病的一般信息,或者您想向患者及其护理人员提供机会,了解肝病症状,治疗,测试,移植和患者支持计划的更多信息,请访问我们的 患者与护理人员 部分。 以下提供其他专业教育资源,帮助您有效识别,应对和解决您的诊治病患中遇到的肝脏健康问题。 所提供的链接信息的相关性与科学价值,已由加拿大肝脏基金会医疗咨询委员会审查,并得到来源许可:

Biliary Atresia

“The Canadian Biliary Atresia Registry (CBAR) is a collaboration between the Canadian Pediatric Hepatology Research Group (CPHRG) and the Canadian Association of Pediatric Surgeons (CAPS), the two well-established networks in Canada involved with the care of children with biliary atresia.” To access more information for Physicians and Investigators, click here.

Hepatitis B

International Hepatitis B Cure Workshop 2017 This one-day workshop brought together global inter-disciplinary experts to enhance the field of hepatitis B research and to provide an interactive platform to achieve the goal of global hepatitis B cure. The meeting included invited lectures, oral abstract presentations, poster viewing sessions, Q&A sessions, round table discussions and debates.   The slides and videos are now available online. Click here. International Hepatitis B Cure Workshop 2016 This one-day workshop brought together global inter-disciplinary experts to enhance the field of hepatitis B research and to provide an interactive platform to achieve the goal of global hepatitis B cure. The meeting included invited lectures, oral abstract presentations, poster view sessions, Q&A sessions, round table discussions and debates. The slides and videos are now available online. Click here. International Viral Hepatitis Elimination Meeting 2017 The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This meeting will address obstacles on the elimination of viral hepatitis along with strategies for success. Following the framework of the recent World Health Organization goals, the meeting will provide an ideal forum for presenting plans to address the elimination of Hepatitis B and C, with concrete objectives, tangible goals and measurable outcomes. The outcomes will be translated to an updated version of the Toronto Declaration. The slide and videos are now available online. Click here. International Viral Hepatitis Elimination Meeting 2016 The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This meeting will address obstacles on the elimination of viral hepatitis along with strategies for success. Following the framework of the recent World Health Organization goals, the meeting will provide an ideal forum for presenting plans to address the elimination of Hepatitis B and C, with concrete objectives, tangible goals and measurable outcomes. The outcomes will be translated to an updated version of the Toronto Declaration. The slide and videos are now available online. Click here.

Hepatitis C

Hepatitis C Education National Needs Assessment Canadian Liver Foundation and Canadian Association for the Study of the Liver, in partnership with the Canadian Association of Hepatology Nurses (October 2015) Assessment of the current knowledge of healthcare providers in the area of hepatitis C management, including screening and treatment using new antivirals, as well as the educational needs of healthcare providers at a national level. Download the Hepatitis C Education National Needs Assessment here. Educational grant provided by AbbVie Corporation. CanHepC logo 7th Canadian Symposium on the Hepatitis C Virus (HCV) 2018 Toward Elimination of HCV: How to Get There. The videos are now available online. Click here. 6th Canadian Symposium on Hepatitis C Virus 2017 Delivering a Cure for Hepatitis C Infection: What are the Remaining Gaps? The videos are now available online. Click here. 5th Canadian Symposium on Hepatitis C Virus 2016 We’re Not Done Yet – Remaining Challenges in Hepatitis C. The videos are now available online. Click here. 3rd Optimize Workshop: Using DAAS in Patients with Cirrhosis and Liver Recipients This workshop focuses on current and emerging direct-acting individuals (DAAs) which promises to impact greatly the management of hepatitis C both prior to and after transplantation. Patients with cirrhosis, patients waiting on lists for liver transplantation, and liver recipients represent populations with a significant need for effective new therapies. The slides and videos are now available online. Click here. International Viral Hepatitis Elimination Meeting 2017 The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This meeting will address obstacles on the elimination of viral hepatitis along with strategies for success. Following the framework of the recent World Health Organization goals, the meeting will provide an ideal forum for presenting plans to address the elimination of Hepatitis B and C, with concrete objectives, tangible goals and measurable outcomes. The outcomes will be translated to an updated version of the Toronto Declaration. The slide and videos are now available online. Click here. International Viral Hepatitis Elimination Meeting 2016 The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This meeting will address obstacles on the elimination of viral hepatitis along with strategies for success. Following the framework of the recent World Health Organization goals, the meeting will provide an ideal forum for presenting plans to address the elimination of Hepatitis B and C, with concrete objectives, tangible goals and measurable outcomes. The outcomes will be translated to an updated version of the Toronto Declaration. The slide and videos are now available online. Click here.


Hepatic Encephalopathy Hepatic Encephalopathy: Explore the Neuropsychiatric Consequences of Cirrhosis Prepared by: Dr. Christopher Rose, Dr. Hermant Shah, Dr. Puneeta Tandon and Dr. Philip Wong (June 2017) A title that says Module 1 Introduction to cirrhosis and its complications Click on the above image and save the Powerpoint Show to view the slides. Module 1: Chronic Liver Disease & Cirrhosis: An Introduction Hepatic Encephalopathy: Overview Hepatic Encephalopathy: Pathophysiology Hepatic Encephalopathy: Clinical Classification Covert Hepatic Encephalopathy: West Haven/Conn Score (0-1) Covert Hepatic Encephalopathy: Testing A title that says Module 2 Overt HE Click on the above image and save the Powerpoint Show to view the slides. Module 2: Overt HE Nonabsorbable Disaccharides: Lactulose Dietary Modification: BCAA’s(Branched-Chain Amino Acids) Nutrition in cirrhosis For a video version of the slides with voice-over narration, please click here.


Hepatocellular Carcinoma (Liver Cancer) Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting: Consensus, Controversies and Future Directions The slides and videos are now available online. Click here.


Liver Disease

2018 Canadian Liver Meeting The 2018 Canadian Liver Meeting was a collaborative effort of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CANHEPC) and the Canadian Association of Hepatology Nurses (CAHN). The meeting program offered a forum for presentation and discussion of basic science, translational and clinical aspects of liver disease. This was a unique opportunity to exchange ideas, promote collaboration and foster knowledge translation among Canadian researchers, healthcare practitioners and community-based groups with interest in Hepatology. Slides are now available online. Click here. Liver Disease in Canada: A Crisis in the Making (April 2013) Canadian Liver Foundation sounds the alarm on looming public health crisis The Canadian Liver Foundation released “Liver Disease in Canada: A Crisis in the Making” – the first comprehensive report on liver disease in Canada. Findings include close to a 30 per cent increase in deaths from liver disease in the eight years from 2000-2007, with Ontario, Quebec, Alberta and British Columbia being hit hardest. Click here to download.


Lysosomal Acid Lipase Deficiency (LALD) Webinar : The Role of Pathology in Diagnosing Lysomal Acid Lipase Deficiency (LAL-D) Presented by: Dr. Subrata Chakrabarti, Chair, Department of Pathology and Laboratory Medicine at Western University and Chief of Pathology and Laboratory Medicine at London Health Sciences Centre & St. Joseph’s Health Care, London, Ontario, Canada. Lysosomal Acid Lipase Deficiency (LAL-D) is an autosomal recessive lysosomal storage disorder [previously known as Wolman Disease (infants) and Cholesteryl Ester Storage Disease (children and adults)]. In pediatric and adult patients, nearly 50% progress to fibrosis, cirrhosis or liver transplant within 3 years of onset of symptoms. For Healthcare Professionals: To request access to the webinar video, please click here to fill out the request form.

To access the Canadian Liver Foundation’s Hep C Resource Centre for Healthcare Professionals, click here.

To access the HE Resource Centre for Healthcare Professionals, click here.

Hepatopulmonary Syndrome (HPS) is a condition that affects the lungs of people diagnosed with chronic liver disease. In the lungs, capillaries (small blood vessels that can be found throughout the body) play a crucial role in the oxygenation of the blood. When the liver is severely damaged, the capillaries in the lungs become dilated, affecting the absorption of oxygen by the red blood cells. As a result of the dilated capillaries, the lungs are not able to provide the body with adequate amounts of oxygen, resulting in a condition known as hypoxemia. Most common symptoms of HPS include shortness of breath and difficulty breathing that is relieved when lying down. A common treatment option for HPS is supplemental oxygen. The ultimate cure for HPS is a liver transplant. For more information on Hepatopulmonary Syndrome (HPS) please visit http://hpscare.com/for-practitioners/

Nutrition GuideThe Nutrition in Cirrhosis Guide This Guide covers general topics relevant to all patients with cirrhosis. Specific nutrition issues are also addressed that may be helpful at other times. The Guide is a tool for use throughout your cirrhosis journey. It also includes recipes that are suitable for all individuals and can be modified to accommodate food allergies, dietary restrictions, and preferences. Click here to download a copy. To order a hard copy version, send your request to Publication Orders.

project echo liver ECHO Ontario Liver is a medical education model that supports primary care providers with management of liver diseases, including Hepatitis C, Hepatitis B, Cirrhosis and Fatty Liver. ECHO participants from across the province connect with each other and with an inter-professional specialist team by videoconference for weekly case based learning. Each week, 3-4 cases are presented by ECHO participants. All participants gain knowledge from these case discussions creating a growing network of PCPs skilled in managing liver diseases. Any primary care provider (PCP) who wants to improve their clinical skills and knowledge can participate either individually or as a team. Physicians, Nurse practitioners, nurses, physician assistants or other health professionals can join. The sessions are CME accredited for physicians and may provide continuing professional development hours for other health care professionals. For more information please visit: https://www.echoontario.ca

Biliary Atresia Treating Physicians in Canada “The Canadian Biliary Atresia Registry (CBAR) is a collaboration between the Canadian Pediatric Hepatology Research Group (CPHRG) and the Canadian Association of Pediatric Surgeons (CAPS), the two well-established networks in Canada involved with the care of children with biliary atresia.” To access the Canadian Biliary Atresia Registry and Investigators, click here. Hepatitis C Treating Physicians in Canada Looking for physicians in your area who treat hepatitis C? The physicians in the searchable maps below have indicated that they treat hepatitis C. Please contact them to ask about patient referrals. Maps available through the following links for:

Search Tips: • Search by city, province, postal code, hospital, physician name, etc. • If several physicians are in the same location, view multiple listings using the arrows at the bottom of a physician info box. • Physician database will be updated as new information is received. Please check updated database for each new referral. * If you would like the CLF to add, revise or remove your name from this database, please contact Karen Seto by email or phone at 1 (800) 563-5483 (Extension 4939). Note: The information provided in these directories has been provided by the physicians and have been posted with their permission. The Canadian Liver Foundation assumes no responsibility for any information or services provided by these physicians and the inclusion of their names on these directories does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.

The information links on this page have been chosen based on their content, source and potential usefulness for our site visitors and are provided here as a public service with regard to liver-related issues. However, the Canadian Liver Foundation assumes no responsibility for any information on these sites and the inclusion of a link on this page does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.

会议与研讨

每四个人加拿大人就有一个可能受到肝脏疾病的影响,加拿大肝脏基金会鼓励所有医疗保健提供者寻求机会,继续在肝脏疾病领域的医学教育。

加拿大和世界各地提供教育研讨大会,探究许多形式的肝病,包括非酒精性脂肪性肝病,病毒性肝炎,肝癌,肝移植,肝性脑病,儿科肝病等。

了解以下的会议列表和特色会议,查询有助您提升对肝病认知的,并可帮助您改善社区肝脏健康的活动。

2019国际肝会议和研讨大会

即将举行的重大会议:

加拿大肝脏会议2019

加拿大肝脏会议是加拿大肝脏研究协会(CASL),加拿大丙型肝炎网络(CANHEPC)和加拿大肝病学护士协会(CAHN)的共同举办的活动。

会议提供一个论坛,用于介绍和讨论肝脏疾病的基础科学,转化和临床方面。 这是一个特别的机会,可以令加拿大研究人员,医疗从业人员和对肝病学感兴趣的社区团体进行相互交流,以促进协作并促进知识转化。

会议详情:请 点击此处。
欲了解更多信息,请访问: www.canadianlivermeeting.ca

CASL and the CLF acknowledge the following organizations for their support of our collective mission to improve the liver health of all Canadians through research, education, patient support and advocacy:

PLATINUM SPONSORS:

Intercept Pharma

Gilead Sciences Canada

BRONZE SPONSORS:

abbvie

If you would like the CLF to add or revise your meeting or conference information, please contact Karen Seto by email or phone at 1 (800) 563-5483 (Extension 4939).

注意 :本页面上的信息链接,是根据其内容、来源及其对于网站访问者潜在用途而选择的,且作为一项公共服务,提供与肝脏健康相关的信息。 但是,加拿大肝脏基金会对这些网站上的任何信息不承担任何责任;在此页面上添加链接,也不代表加拿大肝脏基金会对任何相关组织或个人的认证。

我们想听取医学界的意见。 您的意见帮助我们确定满足您的患者和您的社区需求的专业教育计划和资源。 如果您想获取在某一特定领域(如儿科,肝脏健康/预防等)或肝脏疾病类型(如脂肪肝病,肝炎,肝癌, 等等)的信息,请联系Karen Seto 电子邮件 或电话 1-800-563 5483 , (分机4939)。 回到顶部